Clinical Significance of Endoscopic Improvement at 6 Months in Patients With Ulcerative Colitis Treated With Ustekinumab: A Retrospective Real-world Analysis.

ABSTRACT:

Objectives

Ustekinumab (UST), an anti-interleukin-12/23 p40 monoclonal antibody, has emerged as an effective therapeutic option for patients with moderate to severe ulcerative colitis (UC). However, early predictors of long-term treatment response remain unclear. This study aimed to assess whether 6-month endoscopic improvement (EI) predicts sustained clinical remission (CR) in patients with UC treated with UST.

Methods

This was a retrospective observational study performed at Kyorin University Hospital. Patients with active UC (Lichtiger Index ≥ 5) who began UST between June 2020 and July 2023 were included. CR was assessed using the LI at weeks 4, 8, 16, and 24. EI at week 24 and sustained CR at week 56 were evaluated.

Results

Fifty-seven patients were enrolled, and

SUBMITTER: Morikubo H 

PROVIDER: S-EPMC12817195 | biostudies-literature | 2026 Apr

REPOSITORIES: biostudies-literature